https://www.thebodypro.com/tag/croi-conference-on-retroviruses-and-opportunistic-infections

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

To Combat HIV, Sub-Saharan Africa Must Strengthen Its Data Management Systems Img

To Combat HIV, Sub-Saharan Africa Must Strengthen Its Data Management Systems

"Compared to the cost of annual treatment, the investment made in simple in-house systems, mobile data collection platforms and data transmission platforms would be a small cost," argues Ian Sanne.

Community Engagement in HIV Prevention Is a Disaster Management Plan Img

Community Engagement in HIV Prevention Is a Disaster Management Plan

"Community engagement is not disaster prevention, but a disaster management plan," says Morenike Ukpong-Folayan.

HIV Clinical Trials Must Enroll More Women Img

HIV Clinical Trials Must Enroll More Women

"People who are designing the studies, who are funding the studies, need to make [enrolling women] a priority," says Rena Patel, M.D.

Mental Health Complications of HIV Insufficiently Studied Img

Mental Health Complications of HIV Insufficiently Studied

The effect of even well-controlled HIV on the brain is not receiving enough attention. Now that people living with HIV no longer need to focus only on survival, quality-of-life issues must be addressed.

IL-1β Inhibitor Lowers Arterial Inflammation in Adults With Controlled HIV Img

IL-1β Inhibitor Lowers Arterial Inflammation in Adults With Controlled HIV

One subcutaneous dose of canakinumab, a monoclonal antibody to IL-1β, significantly reduced arterial inflammation in 10 individuals with well-controlled HIV.

New HIV Capsid Inhibitor Strongly Stops HIV Replication at Two Steps Img

New HIV Capsid Inhibitor Strongly Stops HIV Replication at Two Steps

A first-in-class HIV-1 capsid inhibitor interrupts replication at two steps of the viral lifecycle and has pharmacokinetic properties that may permit once-monthly or less frequent dosing.

Safety Important in Pre-Exposure Prophylaxis Trials Img

Safety Important in Pre-Exposure Prophylaxis Trials

"If there is compelling evidence that [a certain agent] works, we stop the trial straight away and let the world know what's going on," says Deborah Donnell, Ph.D.

Weekly Injections of Antibody PRO 140 Keep HIV Undetectable in 10 of 16 Patients Img

Weekly Injections of Antibody PRO 140 Keep HIV Undetectable in 10 of 16 Patients

Self-injected monotherapy with PRO 140, a monoclonal antibody that binds to the CCR5 receptor on CD4 cells, maintained viral suppression in 10 of 16 study participants for 41 to 123 weeks.

The Need to Advocate for Fair HIV Drug Prices Img

The Need to Advocate for Fair HIV Drug Prices

"Drug prices are too high and your access to your drugs is in danger. So, wake up and get ready!" says Lynda Dee of the Fair Pricing Coalition.

Higher Baseline Viral Load and Black Race Predict Severe Weight Gain on HIV Treatment Img

Higher Baseline Viral Load and Black Race Predict Severe Weight Gain on HIV Treatment

Among people starting their first antiretroviral therapy regimen, more advanced HIV disease and black race independently predicted severe weight gain through 96 weeks of follow-up.